Education:
Assoc Prof Dr Guodong Liang earned his Bachelor’s degree in Pharmacy from Shenyang Pharmaceutical University in 2012. He continued his studies at the same institution, obtaining a Master’s degree in Pharmaceutical Sciences in 2015. Further advancing his academic career, he completed his Ph.D. in Pharmacology and Toxicology at the Beijing Institute of Pharmacology and Toxicology in 2018. His educational background has provided a strong foundation for his research in peptide-based antiviral strategies.
Professional Experience:
Assoc Prof Dr Guodong Liang is a senior engineer and master tutor at the College of Pharmacy, Inner Mongolia Medical University. In this role, he leads research and teaching initiatives, focusing on peptide-based antiviral therapies. Prior to his current position, Dr. Liang has accumulated extensive experience in peptide research and development. His expertise encompasses the design of peptide fusion inhibitors and contributions to significant research projects funded by various programs, including the Inner Mongolia Natural Science Foundation and Inner Mongolia Medical University. His professional background reflects a commitment to advancing antiviral research and educating the next generation of scientists.
Research Interests:
Assoc Prof Dr Guodong Liang’s research interests are centered around peptide-based antiviral therapies. His work primarily focuses on the development and application of peptide fusion inhibitors to combat viral infections. Notable areas of his research include the design of isopeptide bond bundling superhelixes and their application in creating inhibitors against viruses such as HIV-1 and SARS-CoV-2. Dr. Liang explores innovative methods for developing broad-spectrum antiviral peptide drugs, aiming to enhance the efficacy of treatments for various viral diseases. His research integrates advanced peptide chemistry with practical antiviral applications, contributing to the field of pharmaceutical science.
Skills:
Assoc Prof Dr Guodong Liang possesses a robust skill set in peptide chemistry and antiviral drug development. His expertise includes designing and synthesizing peptide-based fusion inhibitors, with a focus on creating isopeptide bond bundling superhelixes for antiviral applications. Dr. Liang is proficient in advanced techniques for peptide analysis and evaluation, including structural and functional assessments of peptide interactions with viral proteins. His skills extend to securing and managing research funding, conducting collaborative projects, and publishing high-impact scientific papers. With a strong foundation in pharmacology and toxicology, Dr. Liang effectively translates complex scientific concepts into practical antiviral solutions.
Conclution:
Dr. Liang’s pioneering work in peptide-based antiviral research, evidenced by his impactful publications, patents, and innovative projects, demonstrates his significant contributions to the field. His research not only advances the design of targeted antiviral therapies but also lays the groundwork for developing broad-spectrum antiviral drugs, marking him as a leading candidate for the Research for Young Scientist Award.
Publication Tob Noted:
A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity
- Authors: Li, Y.-Y., Liang, G.-D., Chen, Z.-X., Liu, S.-W., Yang, J.
- Journal: Acta Pharmacologica Sinica, 2024
Isopeptide Bond Bundling Superhelix for Designing Antivirals against Enveloped Viruses with Class I Fusion Proteins: A Review
- Authors: Na, H., Liang, G., Lai, W.
- Journal: Current Pharmaceutical Biotechnology, 2023, 24(14), pp. 1774–1783
Hipponorterpenes A and B, two new 14-noreudesmane-type sesquiterpenoids from the juice of Hippophae rhamnoides
- Authors: Zhang, X.-L., Na, H.-Y., Li, P.-S., Liang, G.-D., Hua, H.-M.
- Journal: Phytochemistry Letters, 2022, 52, pp. 82–86
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery
- Authors: Wang, C., Zhao, L., Xia, S., Jiang, S., Liu, K.
- Journal: Journal of Medicinal Chemistry, 2018, 61(19), pp. 8734–8745